These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29691292)
1. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR. Veiga SR; Ge X; Mercer CA; Hernández-Álvarez MI; Thomas HE; Hernandez-Losa J; Ramón Y Cajal S; Zorzano A; Thomas G; Kozma SC Clin Cancer Res; 2018 Aug; 24(15):3767-3780. PubMed ID: 29691292 [No Abstract] [Full Text] [Related]
2. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739 [TBL] [Abstract][Full Text] [Related]
3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225 [TBL] [Abstract][Full Text] [Related]
4. Phenformin and ataxia-telangiectasia mutated inhibitors synergistically co-suppress liver cancer cell growth by damaging mitochondria. Wu T; Zhou S; Qin M; Tang J; Yan X; Huang L; Huang M; Deng J; Xiao D; Hu X; Wu J; Yang X; Li G FEBS Open Bio; 2021 May; 11(5):1440-1451. PubMed ID: 33742560 [TBL] [Abstract][Full Text] [Related]
5. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells. Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295 [TBL] [Abstract][Full Text] [Related]
6. Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs. Hsu CC; Wu LC; Hsia CY; Yin PH; Chi CW; Yeh TS; Lee HC Oncol Rep; 2015 Sep; 34(3):1620-8. PubMed ID: 26133123 [TBL] [Abstract][Full Text] [Related]
7. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751 [TBL] [Abstract][Full Text] [Related]
8. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. Liu M; Gu P; Guo W; Fan X Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
10. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141 [TBL] [Abstract][Full Text] [Related]
11. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219 [TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591 [TBL] [Abstract][Full Text] [Related]
13. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710 [TBL] [Abstract][Full Text] [Related]
14. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999 [TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Wang H; Zhang C; Chi H; Meng Z Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259 [TBL] [Abstract][Full Text] [Related]
16. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma. Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254 [TBL] [Abstract][Full Text] [Related]
18. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227 [TBL] [Abstract][Full Text] [Related]
19. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Ferrín G; Guerrero M; Amado V; Rodríguez-Perálvarez M; De la Mata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070029 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma. Liu Y; Sun L; Su X; Guo S Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]